{"answer":{"query":"eliquis","resolved_as":"name","packages":12,"applications":["NDA202155","NDA220073"],"identity":{"application_numbers":["NDA202155","NDA220073"],"marketing_categories":["NDA"],"labelers":[{"text":"E.R. SQUIBB & SONS, LLC.","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true},{"text":"CAPSULE","untrusted":true},{"text":"TABLET, FOR SUSPENSION","untrusted":true},{"text":"KIT","untrusted":true}],"marketing_start":{"earliest":"2012-12-28","latest":"2025-09-15","packages_with_a_start_date":10}},"price":{"median_negotiated_over_nadac":0.7515000000000001,"packages_compared":6,"packages_listed":12,"negotiated_price_ends":null,"rows":[{"ndc":"00003089321","name":{"text":"Eliquis","untrusted":true},"class":"B","nadac_per_unit":5.51243,"negotiated_per_unit":4.145072,"ratio":0.752,"ful_per_unit":null},{"ndc":"00003089331","name":{"text":"Eliquis","untrusted":true},"class":"B","nadac_per_unit":5.51243,"negotiated_per_unit":4.145072,"ratio":0.752,"ful_per_unit":null},{"ndc":"00003089341","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":4.145072,"ratio":null,"ful_per_unit":null},{"ndc":"00003089421","name":{"text":"Eliquis","untrusted":true},"class":"B","nadac_per_unit":5.52144,"negotiated_per_unit":4.145072,"ratio":0.751,"ful_per_unit":null},{"ndc":"00003089431","name":{"text":"Eliquis","untrusted":true},"class":"B","nadac_per_unit":5.52144,"negotiated_per_unit":4.145072,"ratio":0.751,"ful_per_unit":null},{"ndc":"00003089441","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":4.145072,"ratio":null,"ful_per_unit":null},{"ndc":"00003089470","name":{"text":"Eliquis","untrusted":true},"class":"B","nadac_per_unit":5.52144,"negotiated_per_unit":4.145072,"ratio":0.751,"ful_per_unit":null},{"ndc":"00003089828","name":{"text":"Eliquis","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":3.85,"ratio":null,"ful_per_unit":null},{"ndc":"00003102812","name":{"text":"Eliquis","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":0.48125,"ratio":null,"ful_per_unit":null},{"ndc":"00003102828","name":{"text":"Eliquis","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":0.48125,"ratio":null,"ful_per_unit":null},{"ndc":"00003102884","name":{"text":"Eliquis","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":0.48125,"ratio":null,"ful_per_unit":null},{"ndc":"00003376474","name":{"text":"Eliquis","untrusted":true},"class":"B","nadac_per_unit":5.50699,"negotiated_per_unit":4.145072,"ratio":0.753,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":237.25,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA202155","date":"2031-08-24","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"9326945*PED","productNo":"001"},"latest_patent_expiry":"2031-08-24","latest_exclusivity_expiry":"2028-10-17","dated_barriers":18,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":2,"exclusivities_listed":3,"fact_id":"cbc511a6cb6cd217bb0da974"},{"application":"NDA220073","date":"2041-05-22","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"11896586*PED","productNo":"001"},"latest_patent_expiry":"2041-05-22","latest_exclusivity_expiry":"2028-10-17","dated_barriers":6,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":2,"exclusivities_listed":2,"fact_id":"6edb0138dd4a263887b142d5"}],"label_history":{"events_total":25,"non_cmc_events":20,"counts_by_class":{"LABELING":14,"EFFICACY":4,"REMS":2},"cmc_events":5,"recent_non_cmc_events":[{"application":"NDA202155","submission_no":42,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-06-24","documents":[{"type":"Letter","date":"2026-06-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/202155Orig1s042, 220073Orig1s001ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-06-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202155s042lbl.pdf","untrusted":true}}],"fact_id":"a7dd2ae0beef8dcb54960e69"},{"application":"NDA220073","submission_no":1,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-06-24","documents":[{"type":"Letter","date":"2026-06-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/202155Orig1s042, 220073Orig1s001ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-06-29","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220073s001lbl.pdf","untrusted":true}}],"fact_id":"431b9c2e24c650394cc91537"},{"application":"NDA202155","submission_no":40,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-04-17","documents":[{"type":"Letter","date":"2025-04-28","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/202155Orig1s039, s040ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-12-12","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202155Orig1s039,s040lbl.pdf","untrusted":true}}],"fact_id":"a857fd2b6aea7264d289aff1"},{"application":"NDA202155","submission_no":39,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-04-17","documents":[{"type":"Letter","date":"2025-04-28","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/202155Orig1s039, s040ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-12-12","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202155Orig1s039,s040lbl.pdf","untrusted":true}}],"fact_id":"0f5a74628184dc6cadc4e1c0"},{"application":"NDA202155","submission_no":34,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2021-10-12","documents":[{"type":"Label","date":"2021-10-13","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s034lbl.pdf","untrusted":true}},{"type":"Letter","date":"2021-10-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/202155Orig1s034ltr.pdf","untrusted":true}}],"fact_id":"6ec509df8bd9cf21565da37c"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":7,"te_code_counts":{"AB":2,"NOT_PROVIDED":5},"marketing_status_counts":{"Prescription":7},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA202155","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"ELIQUIS","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"2.5MG","untrusted":true}},{"application":"NDA202155","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"ELIQUIS","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"5MG","untrusted":true}},{"application":"NDA202155","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ELIQUIS","untrusted":true},"form":{"text":"TABLET, FOR SUSPENSION;ORAL","untrusted":true},"strength":{"text":"0.5MG","untrusted":true}},{"application":"NDA220073","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ELIQUIS","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"5MG","untrusted":true}},{"application":"NDA220073","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ELIQUIS SPRINKLE","untrusted":true},"form":{"text":"FOR SUSPENSION;ORAL","untrusted":true},"strength":{"text":"0.15MG","untrusted":true}},{"application":"NDA220073","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ELIQUIS","untrusted":true},"form":{"text":"SUSPENSION;ORAL","untrusted":true},"strength":{"text":"0.15MG","untrusted":true}},{"application":"NDA220073","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ELIQUIS","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"0.5MG","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class I":1},"packages_of_these_applications":10,"most_recent":[{"recall_number":"D-0959-2017","classification":"Class I","status":"Terminated","report_date":"2017-07-19","recall_initiated":"2017-06-05","recalling_firm":{"text":"Bristol-myers Squibb Company","untrusted":true},"reason":{"text":"Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.","untrusted":true},"packages_named":1,"fact_id":"b4279cd50f6980536d00687b"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"APIXABAN","untrusted":true},"recruiting_interventional_count":61,"not_yet_recruiting_count":25,"by_phase":{"PHASE3":18,"PHASE2":4,"NA":14,"PHASE4":21,"PHASE1":2,"EARLY_PHASE1":2},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT07015905","title":{"text":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2025-06-25","link":{"text":"https://clinicaltrials.gov/study/NCT07015905","untrusted":true}},{"nct_id":"NCT07175428","title":{"text":"Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2025-10-20","link":{"text":"https://clinicaltrials.gov/study/NCT07175428","untrusted":true}},{"nct_id":"NCT07493304","title":{"text":"Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2026-08-26","link":{"text":"https://clinicaltrials.gov/study/NCT07493304","untrusted":true}},{"nct_id":"NCT07626411","title":{"text":"Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Regeneron Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2026-08-10","link":{"text":"https://clinicaltrials.gov/study/NCT07626411","untrusted":true}},{"nct_id":"NCT07471139","title":{"text":"SWITCH: Apixaban vs Vitamin K in HM3","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Columbia University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2026-10-15","link":{"text":"https://clinicaltrials.gov/study/NCT07471139","untrusted":true}}],"fact_id":"664a5c02865dd35883930c69"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Pfizer RxPathways","untrusted":true},"type":"manufacturer","url":"https://www.pfizerrxpathways.com/","status":{"state":"limited","effective":"2025-01-01","applies_to":{"text":"Medicare Part D patients requesting help with a Pfizer product covered under their plan","untrusted":true},"detail":{"text":"Pfizer RxPathways states that from 2025-01-01 Medicare Part D patients must first enroll in the Medicare Prescription Payment Plan and submit proof of enrollment with their application, and, before being considered, must apply to all open, relevant diagnosis-specific independent charitable patient assistance programs and submit written proof of any denial. The page that states this is headed 2025 PAP changes; no later update was on the page when read.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.pfizerrxpathways.com/updates","proof_state":"verified"},"needs_status_check":true,"has_offer":false},{"name":{"text":"Bristol Myers Squibb Patient Assistance Foundation","untrusted":true},"type":"manufacturer","url":"https://www.bmspaf.org/","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"BMS Eliquis 360 Support Savings Card","untrusted":true},"type":"manufacturer","url":"https://www.eliquis.bmscustomerconnect.com/afib/savings","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"HealthWell Foundation","untrusted":true},"type":"nonprofit","url":"https://www.healthwellfoundation.org/","status":{"state":"limited","effective":null,"applies_to":{"text":"HealthWell Foundation disease funds, as listed on the homepage when read","untrusted":true},"detail":{"text":"The HealthWell Foundation homepage lists disease funds as Open or Closed when read. Closed funds include Type 2 Diabetes, Migraine and Multiple Sclerosis - Medicare Access; open funds include Multiple Myeloma - Medicare Access, which the page says offers up to $8,000 in prescription drug copayment or Medicare Part B premium assistance. The page carries no fund-level date; the status is as of the read.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.healthwellfoundation.org/","proof_state":"verified"},"needs_status_check":true,"has_offer":false}],"manufacturer_offers":[{"program":"eliquis-copay-card","kind":"copay_card","price_figures":{"payAsLittleAs30DaySupply":10,"payAsLittleAsFirst90DaySupply":10,"payAsLittleAsSubsequent90DayRefills":30,"subsequentRefillsFor":"up to 24 months","maxAnnualBenefit":2000},"conditions":{"text":"The page states the card must be activated and first used by December 31, 2026, expires 24 months from activation, is not applicable to co-pays of $10 or less, and is for patients without prescription coverage through a state or federal healthcare program.","untrusted":true},"limited_time":true,"expires_note":{"text":"Activation and first use must take place by December 31, 2026","untrusted":true},"stated_end_date":"2026-12-31","expired":false,"detail":{"text":"The Eliquis savings-and-support page states a Co-pay Card: pay as little as $10 for a 30-day supply or for the first 90-day supply, as little as $30 for subsequent 90-day refills for up to 24 months, with a maximum annual benefit of $2,000. Activation and first use must take place by December 31, 2026, and the card expires 24 months from activation.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.eliquis.bmscustomerconnect.com/savings-and-support","proof_state":"verified","fact_id":"a10a9b32f732b42d204374a4"},{"program":"eliquis-free-trial-offer","kind":"free_trial","price_figures":{"freeSupplyDays":30,"freeSupplyUpToTablets":74,"usesPerPatientPerLifetime":1},"conditions":{"text":"The page states the offer is for patients who have not previously filled an ELIQUIS prescription and have a valid 30-day prescription; it is limited to one use per patient per lifetime; it cannot be billed to health insurance or any third party, including state or federally funded programs; the card must be activated and used by December 31, 2026 and expires that day.","untrusted":true},"limited_time":true,"expires_note":{"text":"The card expires on December 31, 2026","untrusted":true},"stated_end_date":"2026-12-31","expired":false,"detail":{"text":"The Eliquis savings-and-support page states a Free 30-Day Trial offer: a free 30-day supply (up to 74 tablets) of ELIQUIS for eligible first-time patients with a valid 30-day prescription, one use per patient per lifetime, not billable to insurance or government programs, with the card expiring on December 31, 2026.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.eliquis.bmscustomerconnect.com/savings-and-support","proof_state":"verified","fact_id":"115e47622d239cd6b31140b6"},{"program":"eliquis-direct-purchase","kind":"self_pay","price_figures":{},"conditions":{"text":"The page says a patient who does not have insurance may be eligible to purchase ELIQUIS directly through ELIQUIS 360 Support. No price is stated on this page; it points to a separate pricing information link.","untrusted":true},"limited_time":false,"expires_note":null,"stated_end_date":null,"expired":false,"detail":{"text":"The Eliquis savings-and-support page states that a patient without insurance may be eligible to purchase ELIQUIS directly through ELIQUIS 360 Support. The page gives no price; it links to pricing information that was not read.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.eliquis.bmscustomerconnect.com/savings-and-support","proof_state":"verified","fact_id":"b8c7736ac03052ca2b07ba5f"}],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Apixaban","untrusted":true},"brand":{"text":"Eliquis","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":9936069813.8,"claims":14847081,"beneficiaries":2641941,"average_spending_per_claim_usd":669.22715743,"fact_id":"7195c59418c437cfb7520cbf"},{"year":2021,"gross_spending_usd":12575145852,"claims":17015798,"beneficiaries":3125087,"average_spending_per_claim_usd":739.02768778,"fact_id":"dc979a184175d7d4fdaecbfc"},{"year":2022,"gross_spending_usd":15219812294,"claims":18973041,"beneficiaries":3505142,"average_spending_per_claim_usd":802.18096265,"fact_id":"b6331e9a82a5e5223587029c"},{"year":2023,"gross_spending_usd":18273451967,"claims":21195452,"beneficiaries":3927848,"average_spending_per_claim_usd":862.14023496,"fact_id":"43e6a805e258f22d0ea9e04f"},{"year":2024,"gross_spending_usd":20774929225,"claims":24061332,"beneficiaries":4424796,"average_spending_per_claim_usd":863.41559248,"fact_id":"e12b21a52e88e9b8e6de0b44"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"rems":{"programs":[{"application":"NDA202155","program":{"text":"Eliquis","untrusted":true},"rems_id":"14","in_force":false,"released":true,"moved_to_shared_system":false,"has_etasu":false,"program_date":"2012-12-28","last_modified":"2016-03-02","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=14","other_programs":0,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"bf5f8a83f4477820f13cd9ce"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"medicaid_state_utilization":{"year":2025,"states_with_data":7,"all_states_medicaid_reimbursed_usd":390101.65,"all_states_medicaid_paid_prescriptions":806,"top_states":[{"state":"NC","medicaid_paid_prescriptions":247,"medicaid_reimbursed_usd":130111.51,"total_reimbursed_usd":130665.9,"packages":2,"covers":"fee_for_service_only","fact_id":"e3b6f712c6dd164761be663e"},{"state":"PR","medicaid_paid_prescriptions":167,"medicaid_reimbursed_usd":115603.66,"total_reimbursed_usd":115603.66,"packages":2,"covers":"all_record_types","fact_id":"0b861f30e269381aaf3a50b8"},{"state":"FL","medicaid_paid_prescriptions":90,"medicaid_reimbursed_usd":53759.38,"total_reimbursed_usd":53759.38,"packages":1,"covers":"fee_for_service_only","fact_id":"844a322f8a9f9df295b7ec9a"},{"state":"UT","medicaid_paid_prescriptions":91,"medicaid_reimbursed_usd":48783.98,"total_reimbursed_usd":48784.08,"packages":1,"covers":"fee_for_service_only","fact_id":"019e1f0a3564cfa5c7a6b0e7"},{"state":"NH","medicaid_paid_prescriptions":53,"medicaid_reimbursed_usd":37784.68,"total_reimbursed_usd":37784.68,"packages":1,"covers":"all_record_types","fact_id":"fb6d6210386607838f563ff3"},{"state":"IA","medicaid_paid_prescriptions":66,"medicaid_reimbursed_usd":2779.62,"total_reimbursed_usd":11835.88,"packages":1,"covers":"all_record_types","fact_id":"f274586633fdcda9fcd52bc1"},{"state":"MT","medicaid_paid_prescriptions":92,"medicaid_reimbursed_usd":1278.82,"total_reimbursed_usd":1849.78,"packages":1,"covers":"all_record_types","fact_id":"8a17a8d1ebfc04bd151b2192"}],"unlabelled_state_code_xx":null,"built_from_facts":9,"facts_fee_for_service_only":4,"older_year_facts_not_used":202,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"047c239f1da0d36b5cd1d466","field":"ndc.listing","entity":"ndc:00003089321"},{"fact_id":"c556b6ce8964d259745b43ff","field":"ndc.listing","entity":"ndc:00003089331"},{"fact_id":"4bbb01f7888059701f275ed2","field":"ndc.listing","entity":"ndc:00003089421"},{"fact_id":"9276f90ef768e64b8523e256","field":"ndc.nadac_price","entity":"ndc:00003089321"},{"fact_id":"784e22e691afc75ca64a81f5","field":"ndc.nadac_price","entity":"ndc:00003089331"},{"fact_id":"137d772dd36fe8323c219ff2","field":"ndc.mfp","entity":"ndc:00003089321"},{"fact_id":"8a1be2ae18790c4474f1a700","field":"ndc.mfp","entity":"ndc:00003089331"},{"fact_id":"390fed1776a24b1006c68acc","field":"ndc.mfp","entity":"ndc:00003089341"},{"fact_id":"cbc511a6cb6cd217bb0da974","field":"drug.generic_entry_earliest","entity":"application:NDA202155"},{"fact_id":"db61cc18709cd8f59b59976c","field":"drug.patent","entity":"application:NDA202155"},{"fact_id":"429b6b20b072a2fa6a46adad","field":"drug.exclusivity","entity":"application:NDA202155"},{"fact_id":"6edb0138dd4a263887b142d5","field":"drug.generic_entry_earliest","entity":"application:NDA220073"},{"fact_id":"9f34f45a9f207044f17551eb","field":"drug.patent","entity":"application:NDA220073"},{"fact_id":"3c617225d791939ff928d7f2","field":"drug.exclusivity","entity":"application:NDA220073"},{"fact_id":"a7dd2ae0beef8dcb54960e69","field":"drug.label_event","entity":"application:NDA202155"},{"fact_id":"431b9c2e24c650394cc91537","field":"drug.label_event","entity":"application:NDA220073"},{"fact_id":"a857fd2b6aea7264d289aff1","field":"drug.label_event","entity":"application:NDA202155"},{"fact_id":"0f5a74628184dc6cadc4e1c0","field":"drug.label_event","entity":"application:NDA202155"},{"fact_id":"6ec509df8bd9cf21565da37c","field":"drug.label_event","entity":"application:NDA202155"},{"fact_id":"ea6b96799506e6d7f6858815","field":"drug.te_code","entity":"application:NDA202155"},{"fact_id":"d7c07252c36797b8d3fe9e56","field":"drug.marketing_status","entity":"application:NDA202155"},{"fact_id":"0c6067f1186b310db05c0fc0","field":"drug.te_code","entity":"application:NDA202155"},{"fact_id":"056ff8dbf93e0465077b686d","field":"drug.marketing_status","entity":"application:NDA202155"},{"fact_id":"b03940c46a455030c880721b","field":"drug.marketing_status","entity":"application:NDA202155"},{"fact_id":"c29a7c2508ee43539b3e641d","field":"drug.marketing_status","entity":"application:NDA220073"},{"fact_id":"baf58c031397ec180c44f255","field":"drug.marketing_status","entity":"application:NDA220073"},{"fact_id":"950992467047d7388c7f3dd9","field":"drug.marketing_status","entity":"application:NDA220073"},{"fact_id":"71689e32de7225bf7882f2db","field":"drug.marketing_status","entity":"application:NDA220073"},{"fact_id":"b4279cd50f6980536d00687b","field":"ndc.recall","entity":"ndc:00003089421"},{"fact_id":"664a5c02865dd35883930c69","field":"drug.trial_access","entity":"drug:apixaban"},{"fact_id":"fceda12b103c15aaafe7bdd7","field":"program.status","entity":"program:pfizer-rxpathways"},{"fact_id":"5918f8fc0a9c66589584d99b","field":"program.status","entity":"program:healthwell-foundation"},{"fact_id":"a10a9b32f732b42d204374a4","field":"program.offer","entity":"program:eliquis-copay-card"},{"fact_id":"b8c7736ac03052ca2b07ba5f","field":"program.offer","entity":"program:eliquis-direct-purchase"},{"fact_id":"115e47622d239cd6b31140b6","field":"program.offer","entity":"program:eliquis-free-trial-offer"},{"fact_id":"7195c59418c437cfb7520cbf","field":"drug.partd_spending","entity":"drug:apixaban|eliquis"},{"fact_id":"dc979a184175d7d4fdaecbfc","field":"drug.partd_spending","entity":"drug:apixaban|eliquis"},{"fact_id":"b6331e9a82a5e5223587029c","field":"drug.partd_spending","entity":"drug:apixaban|eliquis"},{"fact_id":"43e6a805e258f22d0ea9e04f","field":"drug.partd_spending","entity":"drug:apixaban|eliquis"},{"fact_id":"e12b21a52e88e9b8e6de0b44","field":"drug.partd_spending","entity":"drug:apixaban|eliquis"},{"fact_id":"bf5f8a83f4477820f13cd9ce","field":"drug.rems","entity":"application:NDA202155"},{"fact_id":"e3b6f712c6dd164761be663e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003089431:NC"},{"fact_id":"0b861f30e269381aaf3a50b8","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003376474:PR"},{"fact_id":"844a322f8a9f9df295b7ec9a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003089470:FL"},{"fact_id":"019e1f0a3564cfa5c7a6b0e7","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003089470:UT"},{"fact_id":"fb6d6210386607838f563ff3","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003376474:NH"},{"fact_id":"f274586633fdcda9fcd52bc1","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003089431:IA"},{"fact_id":"8a17a8d1ebfc04bd151b2192","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00003089431:MT"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}